WHEN ‘IT’S WHEN’
Shortly after COVID-19 became a known global threat, the Operation Warp Speed, an interagency initiative that includes the U.S. Department of Health and Human Services, collaborated with DOD to support development and acquisition of vaccines, diagnostics and therapeu- tics. Tis partnership would leverage the CBRN defense and acquisition expertise of the JPEO-CBRND and its existing rela- tionships to find immediate solutions for DOD and the nation. JPEO-CBRND was perfectly positioned to serve as a liaison among the interagency, industry and academic partners, and was central to enabling and managing the largest contract awards in its history at a record- breaking pace.
“By leveraging existing acquisition strate- gies and equipment, the JPEO-CBRND has helped Operation Warp Speed pave the way for many COVID-19 defense strate- gies,” said Dr. Jason Roos, deputy joint program executive officer for CBRND. “JPEO-CBRND's contributions to the fight against the COVID-19 pandemic have been extraordinary and innovative, and I'm incredibly proud of our team's tireless hard work in support of Opera- tion Warp Speed.”
Led by the Department of Health and Human Services, Operation Warp Speed had an ambitious goal—to deliver 300 million doses of vaccine by the begin- ning of 2021. It would require multiple companies racing to find a viable solu- tion to enter through the proper clinical trials for safe and effective use. Te oper- ation enlisted experts and support from JPEO-CBRND in the field of vaccine development, biological threats, regula- tory matters and acquisition.
In addition to providing support to Opera- tion Warp Speed, JPEO-CBRND worked with the Defense Health Agency (DHA)
18 Army AL&T Magazine Winter 2021 SUPERVISING PROGRESS
Col. Matthew Jones, 436th Airlift Wing commander, and other senior wing leadership stopped by for a short briefing as the aircraft and equipment was going through testing. (U.S. Air Force photo by Roland Balik, 436th Airlift Wing Public Affairs)
on DOD support efforts that included the purchase of COVID-19 diagnostic systems and assays, personal protective equipment and medical test equipment as well as conducting therapeutic research.
JPEO-CBRND worked with U.S. Army Contracting Command to address Opera- tion Warp Speed and DOD requirements using a combination of Federal Acquisition Regulation (FAR) and non-FAR-based contracts. Together, they executed contract actions quickly and obligated funds within weeks instead of months, while JPEO-CBRND provided total program management, medical and biological expertise, and acquisition support to get the best value for the taxpayer. Within six months, JPEO-CBRND facilitated and managed contract procurements of up to $10.8 billion for Operation Warp
Speed, $1 billion in support of DHA, and more than $455 million for DOD. JPEO-CBRND managed the award of these contracts, which were funded with Health and Human Services’ Biomedi- cal Advanced Research and Development Authority and DHA dollars, and mitigated risk by using an existing other-transaction authority mechanism to compress contract negotiations from weeks or months down to days.
Tis efficiency enabled Operation Warp Speed to accelerate delivery of protec- tive and test equipment and to leverage existing scientific research to enter Phase I clinical trials for vaccine development. Long before the COVID-19 pandemic, JPEO-CBRND used this same other- transaction authority, which allows rapid and direct pre-award negotiations with
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176
